Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
United Therapeutics Corp (NASDAQ: UTHR) closed the day trading at $309.22 up 1.26% from the previous closing price of $305.38. In other words, the price has increased by $1.26 from its previous closing price. On the day, 1.31 million shares were traded. UTHR stock price reached its highest trading level at $309.34 during the session, while it also had its lowest trading level at $304.74.
Ratios:
For a better understanding of UTHR, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.09. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 7.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on June 02, 2025, initiated with a Overweight rating and assigned the stock a target price of $405.
BofA Securities Upgraded its Underperform to Neutral on April 21, 2025, while the target price for the stock was maintained at $314.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’25 when MAHON PAUL A sold 11,000 shares for $308.75 per share. The transaction valued at 3,396,249 led to the insider holds 36,781 shares of the business.
PAUL MAHON bought 11,000 shares of UTHR for $3,396,249 on Aug 21 ’25. On Aug 07 ’25, another insider, MAHON PAUL A, who serves as the EVP & GENERAL COUNSEL of the company, sold 11,000 shares for $300.00 each. As a result, the insider received 3,299,981 and left with 36,781 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UTHR now has a Market Capitalization of 13984876544 and an Enterprise Value of 10936164352. As of this moment, United’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.07, and their Forward P/E ratio for the next fiscal year is 10.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.54 while its Price-to-Book (P/B) ratio in mrq is 1.95. Its current Enterprise Value per Revenue stands at 3.553 whereas that against EBITDA is 6.848.
Stock Price History:
The Beta on a monthly basis for UTHR is 0.62, which has changed by -0.14067364 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, UTHR has reached a high of $417.82, while it has fallen to a 52-week low of $266.98. The 50-Day Moving Average of the stock is 3.91%, while the 200-Day Moving Average is calculated to be -5.20%.
Shares Statistics:
Over the past 3-months, UTHR traded about 633.87K shares per day on average, while over the past 10 days, UTHR traded about 689090 shares per day. A total of 45.22M shares are outstanding, with a floating share count of 43.75M. Insiders hold about 3.27% of the company’s shares, while institutions hold 96.94% stake in the company. Shares short for UTHR as of 1755216000 were 2855183 with a Short Ratio of 2.48, compared to 1752537600 on 1600574. Therefore, it implies a Short% of Shares Outstanding of 2855183 and a Short% of Float of 8.290000000000001.
Earnings Estimates
The current rating of United Therapeutics Corp (UTHR) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $6.42, with high estimates of $7.57 and low estimates of $4.24.
Analysts are recommending an EPS of between $28.05 and $24.37 for the fiscal current year, implying an average EPS of $26.59. EPS for the following year is $27.78, with 12.0 analysts recommending between $31.03 and $23.03.
Revenue Estimates
11 analysts predict $820.7M in revenue for the current quarter. It ranges from a high estimate of $936M to a low estimate of $778.4M. As of the current estimate, United Therapeutics Corp’s year-ago sales were $748.9MFor the next quarter, 11 analysts are estimating revenue of $802.5M. There is a high estimate of $821.3M for the next quarter, whereas the lowest estimate is $771.3M.
A total of 13 analysts have provided revenue estimates for UTHR’s current fiscal year. The highest revenue estimate was $3.3B, while the lowest revenue estimate was $3.13B, resulting in an average revenue estimate of $3.22B. In the same quarter a year ago, actual revenue was $2.88BBased on 13 analysts’ estimates, the company’s revenue will be $3.4B in the next fiscal year. The high estimate is $3.6B and the low estimate is $3.07B.
